

Masataka Sawaki

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3797670/publications.pdf](https://exaly.com/author-pdf/3797670/publications.pdf)

Version: 2024-02-01

93
papers

1,399
citations

355432

18
h-index

350564

32
g-index

115
all docs

115
docs citations

115
times ranked

1907
citing authors

#	ARTICLE	IF	CITATIONS
1	Supraclavicular Irradiation Induces Lymphedema in Breast Cancer Patients Treated with Axillary Lymph Node Dissection and Taxane-Containing Chemotherapy. <i>Breast Journal</i> , 2024, 2024, .	1.2	0
2	The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial. <i>Annals of Surgical Oncology</i> , 2023, 30, 3224-3232.	2.0	3
3	Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan. <i>Breast</i> , 2023, 70, 1-7.	2.3	6
4	The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. <i>Breast Cancer</i> , 2022, 29, 234-241.	3.1	103
5	Management of breast cancer in older patients. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 682-689.	1.4	4
6	Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 253-262.	2.3	0
7	Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan. <i>Future Oncology</i> , 2022, 18, 2101-2111.	2.4	5
8	Older patients's™ experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study. <i>European Journal of Oncology Nursing</i> , 2022, 57, 102115.	2.3	3
9	Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1239-1247.	2.0	7
10	Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use. <i>Journal of Breast Cancer</i> , 2022, 25, 296.	1.9	2
11	Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study. <i>Breast</i> , 2022, 66, 245-254.	2.3	4
12	Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan. <i>Breast Cancer</i> , 2021, 28, 1-8.	3.1	11
13	Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. <i>Investigational New Drugs</i> , 2021, 39, 272-277.	2.7	14
14	Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer. <i>Breast Cancer</i> , 2021, 28, 1087-1095.	3.1	2
15	Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women. <i>Human Pathology</i> , 2021, 111, 10-20.	2.4	10
16	Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial. <i>BMC Cancer</i> , 2021, 21, 548.	2.6	12
17	The significance of biopsy scar excision at the time of skin- or nipple-sparing mastectomy with immediate breast reconstruction. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1212-1218.	1.4	1
18	Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 675-683.	2.6	5

#	ARTICLE	IF	CITATIONS
19	MO11-7 The decision of adjuvant treatment using OncotypeDX and outcome in early breast cancer patients. <i>Annals of Oncology</i> , 2021, 32, S304.	1.3	0
20	P17-8 Clinical impact of next-generation sequencing in patients with breast cancer: A single institute study. <i>Annals of Oncology</i> , 2021, 32, S338.	1.3	0
21	A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1471-1474.	1.4	2
22	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462.	5.3	17
23	Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry. <i>European Journal of Cancer</i> , 2021, 154, 157-166.	3.0	7
24	A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 425-434.	2.6	1
25	Differences in baseline risk estimated by physicians and patients with early breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1703-1707.	1.4	1
26	Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. <i>BMC Cancer</i> , 2021, 21, 1269.	2.6	11
27	Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 91-100.	2.6	19
28	The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition. <i>Breast Cancer</i> , 2020, 27, 4-8.	3.1	32
29	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3743-3752.	5.3	57
30	A phase I/II trial of intraoperative breast radiotherapy in an Asian population: 10-year results with critical evaluation. <i>Journal of Radiation Research</i> , 2020, 61, 602-607.	1.8	2
31	Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction. <i>Breast Cancer</i> , 2020, 27, 716-723.	3.1	6
32	Impact of BMI for clinical outcomes in Japanese breast cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 230-240.	1.4	9
33	Utility of regional nodal irradiation in Japanese patients with breast cancer with 3 positive nodes after breast-conserving surgery and axillary lymph node dissection. <i>Molecular and Clinical Oncology</i> , 2020, 13, 48-53.	1.1	1
34	Abstract P3-14-02: A cohort study to evaluate the efficacy and safety of postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT-cohort study). <i>Cancer Research</i> , 2020, , .	0.9	0
35	Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report. <i>World Journal of Clinical Oncology</i> , 2020, 11, 504-509.	2.4	3
36	ASO Author Reflections: The Strengths and Weaknesses of Intraoperative Radiotherapy for Early Breast Cancer and Ipsilateral Tumor Recurrence. <i>Annals of Surgical Oncology</i> , 2019, 26, 660-661.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Presence of small residual malignant lesions in pathologic complete response after neoâ€adjvant chemotherapy in patients with breast cancer. <i>Breast Journal</i> , 2019, 25, 1303-1305.	1.2	1
38	Atezolizumab + nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130. <i>Annals of Oncology</i> , 2019, 30, vi84-vi85.	1.3	0
39	A case of giant cell tumor of the breast, clinically suspected as malignant breast tumor. <i>Surgical Case Reports</i> , 2019, 5, 77.	0.7	8
40	Amyloid tumor of the breast. <i>Surgical Case Reports</i> , 2019, 5, 31.	0.7	11
41	Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy. <i>Breast Journal</i> , 2019, 25, 202-206.	1.2	5
42	A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1320-1327.	2.3	1
43	Multicenter Phase II Study of Intraoperative Radiotherapy of Early Breast Cancer: Ipsilateral Tumor Recurrence. <i>Annals of Surgical Oncology</i> , 2019, 26, 2428-2434.	2.0	14
44	The overall survival of breast cancer patients without adjuvant therapy. <i>Surgery Today</i> , 2019, 49, 610-620.	1.6	2
45	Circulating tumor cells detection in tumor draining vein of breast cancer patients. <i>Scientific Reports</i> , 2019, 9, 18195.	3.5	17
46	TNM classification of malignant tumors (Breast Cancer Study Group). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 228-231.	1.4	37
47	Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan. <i>Breast Cancer</i> , 2018, 25, 539-546.	3.1	3
48	Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery. <i>Breast Cancer</i> , 2018, 25, 583-589.	3.1	5
49	Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma. <i>Breast Cancer</i> , 2018, 25, 560-565.	3.1	15
50	Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan. <i>Breast Cancer</i> , 2018, 25, 60-67.	3.1	3
51	Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 81-87.	2.6	15
52	A case of radiation-associated angiosarcoma after breast cancer. <i>Surgical Case Reports</i> , 2018, 4, 131.	0.7	9
53	The investigation study using a questionnaire about the employment of Japanese breast cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 712-717.	1.4	2
54	Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341878624.	1.1	2

#	ARTICLE	IF	CITATIONS
55	Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 1-7.	2.6	28
56	A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. <i>Breast Cancer</i> , 2018, 25, 729-735.	3.1	12
57	Tailored treatment for elderly breast cancer patients. <i>Annals of Oncology</i> , 2017, 28, ix53.	1.3	0
58	A Case of Breast Metastasis from Rectal Cancer. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	1
59	Current Primary Systemic Therapy and Future Perspectives in patients with HER2-positive Breast Cancer. <i>Annals of Oncology</i> , 2016, 27, vii46.	1.3	0
60	Impact of intraoperative specimen mammography on margins in breast-conserving surgery. <i>Molecular and Clinical Oncology</i> , 2016, 5, 269-272.	1.1	17
61	Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer. <i>SpringerPlus</i> , 2016, 5, 1095.	1.2	11
62	Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. <i>BMC Cancer</i> , 2016, 16, 248.	2.6	84
63	Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy. <i>Breast Cancer</i> , 2016, 23, 190-194.	3.1	19
64	Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer. <i>Breast Cancer</i> , 2016, 23, 195-201.	3.1	14
65	A phase I/II trial of intraoperative breast radiotherapy in an Asian population: 5-year results of local control and cosmetic outcome. <i>Radiation Oncology</i> , 2015, 10, 150.	2.8	18
66	Anti-HER2 Therapy in Elderly Breast Cancer Patients. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 263-266.	0.9	1
67	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 37.	1.9	0
68	Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer. <i>Oncology Letters</i> , 2014, 8, 1707-1712.	1.9	10
69	Feasibility of intraoperative radiation therapy for early breast cancer in Japan: a single-center pilot study and literature review. <i>Breast Cancer</i> , 2014, 21, 415-422.	3.1	10
70	Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 673-683.	2.4	19
71	A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 991-998.	2.4	6
72	High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study. <i>Oncology Letters</i> , 2012, 3, 61-65.	1.9	15

#	ARTICLE	IF	CITATIONS
73	Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 1950-1957.	2.7	37
74	Phase I/II study of intraoperative radiotherapy for early breast cancer in Japan. <i>Breast Cancer</i> , 2012, 19, 353-359.	3.1	21
75	Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. <i>Breast Cancer</i> , 2012, 19, 253-258.	3.1	15
76	Patterns of Lymph Node Metastases in Papillary Thyroid Carcinoma: Results from Consecutive Bilateral Cervical Lymph Node Dissection. <i>World Journal of Surgery</i> , 2011, 35, 1560-1566.	1.4	30
77	The Effect of Toremifene on Lipid Metabolism Compared with That of Tamoxifen in vitro. <i>Gynecologic and Obstetric Investigation</i> , 2011, 71, 213-216.	1.6	5
78	Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients. <i>Surgery Today</i> , 2010, 40, 831-835.	1.6	10
79	Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. <i>Breast Cancer</i> , 2010, 17, 254-260.	3.1	11
80	Comprehensive geriatric assessment in elderly breast cancer patients. <i>Breast Cancer</i> , 2010, 17, 183-189.	3.1	25
81	Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. <i>Breast</i> , 2010, 19, 370-376.	2.3	3
82	The Feasibility Study of Docetaxel in Patients with Anaplastic Thyroid Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 596-599.	1.4	48
83	Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 435-441.	2.6	145
84	A Phase I Study of Intraoperative Radiotherapy for Early Breast Cancer in Japan. <i>World Journal of Surgery</i> , 2009, 33, 2587-2592.	1.4	12
85	Long Term Parathyroid Function Following Total Parathyroidectomy with Autotransplantation in Adult Patients with MEN2A. <i>Endocrine Journal</i> , 2009, 56, 545-551.	1.7	17
86	Neuroendocrine tumor in the breast. <i>Radiation Medicine</i> , 2008, 26, 28-32.	0.9	48
87	High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. <i>Breast Cancer</i> , 2006, 13, 172-178.	3.1	52
88	Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience. <i>Breast Cancer</i> , 2006, 13, 329-333.	3.1	8
89	Adrenal Incidentaloma: Review of 197 Patients and Report of a Drug-Related False-Positive Urinary Normetanephrine Result. <i>Surgery Today</i> , 2006, 36, 961-965.	1.6	27
90	Intraoperative Radiotherapy for Early Breast Cancer. , 0, , .		0

#	ARTICLE	IF	CITATIONS
91	ASO Author Reflections: How Can We Eliminate Breast Surgery in Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 0, , .	2.0	0
92	Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 0, 26, .	1.9	1
93	Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study. <i>Breast Cancer Research and Treatment</i> , 0, , .	2.6	0